Trial Profile
A Phase I Study of PLX038 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs DFP 13318 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Prolynx
- 11 Jul 2023 Status changed from recruiting to completed.
- 25 Jan 2019 Planned End Date changed from 1 Jun 2018 to 1 Jun 2020.
- 25 Jan 2019 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.